Belite Bio Files Regulatory Applications in UK, Switzerland, and Singapore
Belite Bio, Inc. (BLTE) submitted Marketing Authorization Applications for its drug candidate, tinlarebant, in the United Kingdom, Switzerland, and Singapore. The regulatory submissions were filed through the Access Consortium to evaluate the therapy as a treatment for Stargardt disease type 1, a rare genetic eye condition.
The coordinated filings extend the biopharmaceutical company's international regulatory reach into three territories that currently lack approved therapies for Stargardt disease type 1. Using the Access Consortium framework enables simultaneous regulatory evaluations across health authorities, which may shorten review timelines and clear a path toward initial international market approvals.
These submissions build on momentum from a Phase 3 clinical trial that met its primary endpoint. Beyond the Access Consortium applications, tinlarebant is under Priority Review with a New Drug Application in the United States and has Sakigake accelerated review status in Japan. Shares of Belite Bio, Inc. (BLTE) closed up 0.83 percent at $153.10 following the update.
Key points
- Belite Bio, Inc. (BLTE) submitted Marketing Authorization Applications for tinlarebant in the UK, Switzerland, and Singapore for Stargardt disease type 1.
- The regulatory filings were submitted through the Access Consortium to enable parallel reviews across health authorities.
- The target markets currently have no approved therapies for Stargardt disease type 1.
- Tinlarebant also holds Priority Review status in the United States and Sakigake accelerated review designation in Japan.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What drug did Belite Bio file for regulatory approval?
Belite Bio filed Marketing Authorization Applications for tinlarebant to treat Stargardt disease type 1, a rare eye condition with no currently approved therapies in the targeted regions.
Which countries are included in Belite Bio's new regulatory filings?
The company submitted applications in the United Kingdom, Switzerland, and Singapore using the Access Consortium framework for parallel review.
What is the regulatory status of tinlarebant in the U.S. and Japan?
In the United States, tinlarebant is undergoing Priority Review under a New Drug Application. In Japan, the drug holds Sakigake designation for accelerated review.